Satellos Bioscience Inc
MSCL
Company Profile
Business description
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
Contact
200 Bay Street
Suite 2800, Royal Bank Plaza, South Tower
TorontoONM5J 2J1
CANT: +1 647 660-1780
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
The beaten down healthcare giant remains cheap on turnaround potential.
stocks
ASX top pick remains cheap with narrowing brand focus
Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.70 | 71.20 | 0.81% |
| CAC 40 | 8,168.33 | 6.50 | 0.08% |
| DAX 40 | 24,203.41 | 8.10 | 0.03% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,278.66 | 23.85 | 0.23% |
| HKSE | 24,182.58 | 225.38 | -0.92% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,217.27 | 38.00 | 0.06% |
| NZX 50 Index | 13,202.16 | 51.49 | -0.39% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,633.20 | 69.70 | 0.81% |
| SSE Composite Index | 3,987.01 | 6.21 | -0.16% |